Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet

doi:10.3748/wjg.v9.i3.495

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 3

This Article

Reference Citation Analysis (1)

(0)

(6589)

(75)

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Colorectal Cancer

World J Gastroenterol. Mar 15, 2003; 9(3): 495-498
Published online Mar 15, 2003. doi: 10.3748/wjg.v9.i3.495

Table 6 Comparison of fve-year survival rate, survival period of resected colorectal cancer patients in vaccination group with positive and negative DTH reaction

DTH reactions	n	5-year survival cases	Survival rate^b	^aSurvival period (^-x ± s)
Positive group	10	8	80%	4.7 ± 0.67
Negative group	10	3	30%	3.5 ± 1.80

χ² test ^aP < 0.05,

^bP < 0.0 1 vs negative group.

Full Size Table

Citation: Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet. World J Gastroenterol 2003; 9(3): 495-498
URL: https://www.wjgnet.com/1007-9327/full/v9/i3/495.htm
DOI: https://dx.doi.org/10.3748/wjg.v9.i3.495

Liang W, Wang H, Sun TM, Yao WQ, Chen LL, Jin Y, Li CL, Meng FJ. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive traet. World J Gastroenterol 2003; 9(3): 495-498 [PMID: 12632504 DOI: 10.3748/wjg.v9.i3.495]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.